Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
Ultragenyx Pharmaceutical (RARE) aims for profitability by 2027, driven by gene therapy launches and potential next-gen versions of Crysvita. CEO Kakkis reported positive early interest in FAYUVI and GENGLYCOS, with launch data expected in January. The company is also discussing setrusumab's next steps with the FDA after a missed endpoint in the ORBIT study and is studying DTX301 for ornithine transcarbamylase deficiency.

